Abstract:Key PointsThe development of simultaneous resistance to multiple drugs, with varying chemical structures and targets, is a major obstacle to effective cancer therapy.Studies indicate that there are three major mechanisms of multidrug resistance (MDR): decreased uptake of water-soluble drugs; various changes in cells that affect the ability of cytotoxic drugs to kill cells; and increased energy-dependent efflux of hydrophobic drugs.Removal of hydrophobic drugs from cells is the most commonly encountered mechanism of multidrug resistance (MDR), and ATP-binding cassette (ABC) transporters have a key role in this process.The ABC transporter family of proteins comprises seven subclasses that are labelled A–G, and these proteins have been shown to be essential for many cellular processes that require transport of substrates across cell membranes, with several members of this family being involved in the absorption, excretion and distribution of drugs.ABC transporters have broad substrate specificity, and the abundance of ABC transporter proteins goes some way to explaining the difficulties faced during the past 20 years when attempting to circumvent ABC-mediated MDR in vivo. Research has focused on the development of drugs that either evade efflux or inhibit the function of efflux transporters, and although progress in this area has been slow, the rationale for this approach is still strong.Several ABC transporters have been found to be overexpressed in cancer cell lines cultured under selective pressure, with at least 12 ABC transporters from four ABC subfamilies implicated in the drug resistance of cells maintained in tissue culture. Studies have shown that the major mechanism of MDR in most cultured cancer cells involves P-glycoprotein (Pgp; MDR1; ABCB1), multidrug resistance associated-protein 1 (MRP1, also known as ABCC1) or ABCG2.Despite significant advances in knowledge of the biochemistry and substrate specificity of ABC transporters since the first description of MDR, translation of this knowledge from the bench to the bedside has proved to be difficult. Only inhibitors of Pgp, and to a lesser extent MRP1 and ABCG2, have been evaluated in clinical trials, and the development of several inhibitors has been discontinued. However, some improved compounds are currently in clinical trials, and it is hoped that the lessons learned from earlier trials will improve the chance of success.Alternative strategies to overcome ABC-transporter-mediated MDR are also emerging, including engaging, evading or exploiting efflux-based resistance mechanisms.

Interaction of tyrosine kinase inhibitors with the MDR- related ABC transporter proteins.

Tyrosine Kinase Inhibitors Enhanced the Efficacy of Conventional Chemotherapeutic Agent in Multidrug Resistant Cancer Cells.

The Role of Organic Cation Transporters in the Pharmacokinetics, Pharmacodynamics and Drug-Drug Interactions of Tyrosine Kinase Inhibitors

Clinically-Relevant ABC Transporter for Anti-Cancer Drug Resistance

Current Understanding of Interactions Between Nanoparticles and ABC Transporters in Cancer Cells.

ABC Transporter Inhibitors in Reversing Multidrug Resistance to Chemotherapy

Understanding of Human ATP Binding Cassette Superfamily and Novel Multidrug Resistance Modulators to Overcome MDR

The Therapeutic Potential of Targeting ABC Transporters to Combat Multi-Drug Resistance

Progress of Research on ABC Transporters in Tumor Multidrug Resistance

Mechanisms of Acquired Resistance to Tyrosine Kinase Inhibitors

ABC transporters affects tumor immune microenvironment to regulate cancer immunotherapy and multidrug resistance.

Alk Tyrosine Kinase Inhibitors In Drug Sensitization

Modulating the Function of ABCB1: in Vitro and in Vivo Characterization of Sitravatinib, a Tyrosine Kinase Inhibitor.

Recent advances regarding the role of ABC subfamily C member 10 (ABCC10) in the efflux of antitumor drugs

Dacomitinib antagonizes multidrug resistance (MDR) in cancer cells by inhibiting the efflux activity of ABCB1 and ABCG2 transporters.

Transporter-Mediated Cellular Distribution of Tyrosine Kinase Inhibitors as a Potential Resistance Mechanism in Chronic Myeloid Leukemia

Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective

Targeting multidrug resistance in cancer

Metabolic activation of tyrosine kinase inhibitors: recent advance and further clinical practice

Insight to Pharmacokinetics of TKIs: Optimizing Practical Guidelines for Individualized Therapy

Pleiotropic Roles of ABC Transporters in Breast Cancer